Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly Return on Capital Employed of 52.87% in Q1 2026, up 3.53% quarter-over-quarter from 54.81% in Q4 2025, and up 2229.0% on a YoY basis from 2.27% in Q1 2025.
Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Aclaris Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 52.87% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2229.0% year-over-year to 52.87%; the TTM figure through Mar 2026 stood at 52.87% (up 2229.0% YoY), while the FY2025 annual figure was 47.22%, up 3285.0% from the prior year.
- Return on Capital Employed was 52.87% for Q1 2026 at Aclaris Therapeutics, up from 54.81% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.28% in Q3 2024 to a low of 97.83% in Q3 2025.
- Historically, Return on Capital Employed has averaged 55.03% across 5 years, with a median of 52.87% in 2026.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 3101 bps in 2024, then tumbled 6755 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 37.57% in 2022, then plunged by 46 bps to 55.03% in 2023, then tumbled by 52 bps to 83.6% in 2024, then soared by 34 bps to 54.81% in 2025, then gained by 4 bps to 52.87% in 2026.
- The last three Return on Capital Employed figures came in at 52.87% (Q1 2026), 54.81% (Q4 2025), and 97.83% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | -52.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.87% |
| Dec 31, 2025 | -54.81% |
| Sep 30, 2025 | -97.83% |
| Jun 30, 2025 | -87.92% |
| Mar 31, 2025 | -75.17% |
| Dec 31, 2024 | -83.60% |
| Sep 30, 2024 | -30.28% |
| Jun 30, 2024 | -44.38% |
| Mar 31, 2024 | -52.14% |
| Dec 31, 2023 | -55.03% |
| Sep 30, 2023 | -61.29% |
| Jun 30, 2023 | -53.22% |
| Mar 31, 2023 | -45.05% |
| Dec 31, 2022 | -37.57% |
| Sep 30, 2022 | -33.07% |
| Jun 30, 2022 | -35.20% |
| Mar 31, 2022 | -36.06% |
| Dec 31, 2021 | -38.27% |
| Sep 30, 2021 | -31.17% |
| Jun 30, 2021 | -33.63% |